Kavish J Bhansing1, Piet L C M van Riel1, Baziel G M van Engelen1, Jaap Fransen1, Madelon C Vonk2. 1. From the Department of Rheumatology, and Department of Quality of Health Care, and Department of Neurology, Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.K.J. Bhansing, MD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center; P.L. van Riel, MD, PhD, Department of Quality of Health Care, Institute for Health Sciences, Radboud University Medical Center; B.G. van Engelen, MD, PhD, Department of Neurology, Institute for Health Sciences, Radboud University Medical Center; J. Fransen, PhD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center; M.C. Vonk, MD, PhD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center. 2. From the Department of Rheumatology, and Department of Quality of Health Care, and Department of Neurology, Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.K.J. Bhansing, MD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center; P.L. van Riel, MD, PhD, Department of Quality of Health Care, Institute for Health Sciences, Radboud University Medical Center; B.G. van Engelen, MD, PhD, Department of Neurology, Institute for Health Sciences, Radboud University Medical Center; J. Fransen, PhD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center; M.C. Vonk, MD, PhD, Department of Rheumatology, Institute for Health Sciences, Radboud University Medical Center. Madelon.Vonk@radboudumc.nl.
Abstract
OBJECTIVE: Studies on mortality associated with patients with systemic sclerosis (SSc) and myopathy have been limited by heterogeneous definitions of muscle involvement. The objective of this study is to determine whether homogeneous-defined SSc/polymyositis overlap (SSc-PM overlap) is associated with a worse survival rate compared with SSc without PM. METHODS: Data from the Nijmegen Systemic Sclerosis cohort were used. Incidence rates were calculated from the observed number of deaths and followup time. Survival analysis using Cox proportional hazard modeling was performed to compare survival among patients with SSc and patients with SSc-PM overlap, including controlling for confounders. All patients with SSc-PM fulfilled the Bohan and Peter criteria for PM. RESULTS: There were 24 patients with SSc-PM (5.7%) and 396 patients with SSc (94.2%). The 5- and 10-year cumulative survival rates from diagnosis were 82% and 68% for the SSc-PM group and 93% and 87% for the SSc group, respectively. Multivariate survival analysis revealed an adjusted HR of 2.34 (95% CI 1.09-5.02) for SSc-PM compared with SSc, with age at diagnosis, modified Rodnan skin score, diffuse cutaneous subtype, and male sex included as confounders. The most common cause of death among patients with SSc-PM overlap was cardiopulmonary involvement (63%), which was similar to the patients with SSc (51%). CONCLUSION: Patients with SSc-PM overlap have a worse survival rate compared with patients with SSc.
OBJECTIVE: Studies on mortality associated with patients with systemic sclerosis (SSc) and myopathy have been limited by heterogeneous definitions of muscle involvement. The objective of this study is to determine whether homogeneous-defined SSc/polymyositis overlap (SSc-PM overlap) is associated with a worse survival rate compared with SSc without PM. METHODS: Data from the Nijmegen Systemic Sclerosis cohort were used. Incidence rates were calculated from the observed number of deaths and followup time. Survival analysis using Cox proportional hazard modeling was performed to compare survival among patients with SSc and patients with SSc-PM overlap, including controlling for confounders. All patients with SSc-PM fulfilled the Bohan and Peter criteria for PM. RESULTS: There were 24 patients with SSc-PM (5.7%) and 396 patients with SSc (94.2%). The 5- and 10-year cumulative survival rates from diagnosis were 82% and 68% for the SSc-PM group and 93% and 87% for the SSc group, respectively. Multivariate survival analysis revealed an adjusted HR of 2.34 (95% CI 1.09-5.02) for SSc-PM compared with SSc, with age at diagnosis, modified Rodnan skin score, diffuse cutaneous subtype, and male sex included as confounders. The most common cause of death among patients with SSc-PM overlap was cardiopulmonary involvement (63%), which was similar to the patients with SSc (51%). CONCLUSION:Patients with SSc-PM overlap have a worse survival rate compared with patients with SSc.
Authors: María Pilar Cruz-Domínguez; Grettel García-Collinot; Miguel Angel Saavedra; Daniel H Montes-Cortes; Rubén Morales-Aguilar; Rosa Angélica Carranza-Muleiro; Olga L Vera-Lastra; Luis J Jara Journal: Rheumatol Int Date: 2017-05-29 Impact factor: 2.631
Authors: Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo Journal: Rheumatol Int Date: 2017-09-02 Impact factor: 2.631
Authors: Sang Wan Chung; In Seol Yoo; Jinhyun Kim; Seong Wook Kang; Mihye Kwon; Chung Il Joung; In Ah Choi; Sung Hae Chang; Mi Il Kang; Seung Jae Hong; Yeon Ah Lee Journal: Yonsei Med J Date: 2021-05 Impact factor: 2.759
Authors: Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Tibor Béldi; Anett Vincze; Erika Zilahi; József Varga; Gabriella Szűcs; Katalin Dankó; Zoltán Griger Journal: Biomed Res Int Date: 2022-05-02 Impact factor: 3.246